<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62608">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290873</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-006</org_study_id>
    <nct_id>NCT02290873</nct_id>
  </id_info>
  <brief_title>A Phase III of Remimazolam in Patients Undergoing Colonoscopy</brief_title>
  <official_title>A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS7056) Compared to Placebo and Midazolam in Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blind, randomized, placebo and active controlled, multi-center,
      parallel group study comparing remimazolam to placebo, with an additional open-label arm for
      midazolam, in patients undergoing a colonoscopy for diagnostic or therapeutic reasons.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of Procedure</measure>
    <time_frame>From start to end of colonoscopy</time_frame>
    <description>Measured by completion of colonoscopy, no requirement for an alternative sedative and no requirement for more than 5 top-ups of study medication within any 15 minute period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to start of procedure</measure>
    <time_frame>From first dose of study drug until insertion of the colonoscope</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak sedation</measure>
    <time_frame>From first dose of study drug until the lowest level of sedation, which has occurred during the colonoscopy procedure.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ready for discharge</measure>
    <time_frame>From the end of the colonoscopy and after the last dose of study drug, until discharge, expected to be the same day.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fully alert</measure>
    <time_frame>From the last dose of study drug, until the patient has recovered to fully alert. Expected to be the same day.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>From first dose of study drug until Day 4, or resolution of any ongoing adverse events.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo iv for sedation induction and maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Remimazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>For induction of maintenance and sedation</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled to undergo a colonoscopy.

        Exclusion Criteria:

          -  patients with known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or
             a medical condition such that these agents are contra-indicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners Inc</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 14, 2016</lastchanged_date>
  <firstreceived_date>November 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
